Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age, endocrine therapy persistence, and recurrence risk in hormone receptor-positive early breast cancer: clarifying a long-standing clinical question.

Chinese clinical oncology·2026
Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026
Same author

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.

Breast care (Basel, Switzerland)·2026
Same author

Stability of potato glycoalkaloids under heating conditions - Reactions with fatty acids.

Current research in food science·2026
Same author

AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

The community engagement and empowerment cycle: FAIRagro's framework to foster cultural change towards FAIR RDM practices in agrosystem science and beyond.

Journal of integrative bioinformatics·2026

Related Experiment Video

Updated: Jun 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Node-Negative Breast Cancer: Which Patients Should Be Treated?

Marcus Schmidt1

  • 1Department of Obstetrics and Gynecology, Johannes Gutenberg University, Mainz, Germany.

Breast Care (Basel, Switzerland)
|November 16, 2010
PubMed
Summary

Accurate breast cancer risk assessment is crucial. New tumor markers like urokinase-type plasminogen activator (uPA)/plasminogen activator inhibitor 1 (PAI-1) and gene assays aim to personalize treatment and avoid overtreatment in early-stage patients.

More Related Videos

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
11:49

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jun 6, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
11:49

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Clinical Trials

Background:

  • Adjuvant systemic therapy significantly improves early-stage breast cancer outcomes.
  • Chemotherapy benefits may be modest in node-negative patients, risking overtreatment.
  • Current risk classifications (St. Gallen, Adjuvant! online) have limitations in specificity.

Purpose of the Study:

  • To highlight the need for more reliable prognostic factors beyond clinicopathologic risk classifications.
  • To introduce urokinase-type plasminogen activator (uPA)/plasminogen activator inhibitor 1 (PAI-1) and gene expression assays as promising tumor markers.
  • To emphasize the goal of personalizing breast cancer treatment and reducing patient toxicity.

Main Methods:

  • Review of current adjuvant therapy strategies and risk stratification methods in early-stage breast cancer.
  • Identification and discussion of recommended tumor markers by the American Society of Clinical Oncology.
  • Mention of ongoing clinical trials (NNBC-3, MINDACT, TAILORx) investigating these markers in node-negative breast cancer.

Main Results:

  • Urokinase-type plasminogen activator (uPA)/plasminogen activator inhibitor 1 (PAI-1) and multiparameter gene expression assays are recommended prognostic markers.
  • These markers are under investigation in large clinical trials for node-negative breast cancer.
  • The studies aim to improve risk quantification for individual patients.

Conclusions:

  • More reliable prognostic factors are needed to spare patients unnecessary chemotherapy toxicity.
  • Tumor markers like uPA/PAI-1 and gene expression assays hold promise for personalized breast cancer treatment.
  • Future clinical trials will guide tailored therapeutic decisions, leading to more personalized recommendations.